Cargando…
BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance
BACKGROUND: BCR-ABL1 mutation analysis is recommended for chronic myeloid leukaemia patients. However, mutations may become undetectable after changing therapy, and it is unknown whether they have been eradicated. METHODS: We examined longitudinal data of patients with imatinib-resistant mutations,...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776970/ https://www.ncbi.nlm.nih.gov/pubmed/23799845 http://dx.doi.org/10.1038/bjc.2013.318 |